Author

Zhuowei Wang

Zhujiang Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Amy Y. CheniD· 2 shared Austin T. GaoiD· 2 shared Bruce T. LahniD· 2 shared Chinnuwat SanguansermsriiD· 2 shared Cole K. ZhengiD· 2 shared Edi Setiawan TehuteruiD· 2 shared Hany Abueita· 2 shared Jack F. Hong· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Amy Y. ChenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Twelve-Month Outcomes of Intrathecal Vesemnogene Lantuparvovec for Spinal Muscular Atrophy in Children Younger than 24 Months in Low- and Middle- Income Countries

Lock Hock Ngu, Qingling Mo, Shiqi Li, Tsun-Haw Toh, Jia Ni Lee, Kok Chong Lim, Edi Setiawan Tehuteru, Rahmi Lestari, Chinnuwat Sanguansermsri, Hany Abueita, Samson Gwer, Li Li, Zhuowei Wang, Salman Kirmani, Julia X. Chen, , Austin T. Gao

This study evaluates the 12-month outcomes of vesemnogene lantuparvovec, an intrathecal gene therapy for SMA in children under 24 months in LMICs, showing safety and motor milestone improvements.

medRxiv · May 30, 2026 · PreprintGenetic & Genomic Medicine

Safety and Efficacy of Vesemnogene Lantuparvovec, an AAV-Based Gene Therapy in Young Children Under 24 Months with Spinal Muscular Atrophy in Low- and-Middle- Income Countries. Second Interim Report (August 2025).

This paper reports on a phase 1 trial of vesemnogene lantuparvovec, an affordable gene therapy for SMA, showing safety and improved motor milestones in young children.

medRxiv · Apr 13, 2025 · PreprintGenetic & Genomic Medicine